Crucell (AMS:CRXL)

QUOTE AND NEWS
Marketwire  Oct 28  Comment 
LEIDEN, NETHERLANDS -- (Marketwire) -- 10/28/10 -- Dutch biopharmaceutical company Crucell N.V. (NASDAQ: CRXL) (SWISS: CRX) today announced that it has put a temporary hold on all shipments of its fully liquid pentavalent vaccine Quinvaxem® and its
Marketwire  Oct 6  Comment 
LEIDEN, NETHERLANDS -- (Marketwire) -- 10/06/10 -- Johnson & Johnson's resources and international reach will accelerate Crucell's growth and further expand its potential New Brunswick, N.J., and Leiden, the Netherlands, 6 October 2010 - Johnson &
Marketwire  Sep 22  Comment 
LEIDEN, NETHERLANDS -- (Marketwire) -- 09/22/10 -- Study to Test New Tuberculosis Vaccine in Infants Leiden, The Netherlands / Rockville, MD, USA (September 22, 2010) - Dutch biopharmaceutical company Crucell N.V. (Euronext, Nasdaq: CRXL) (SWISS:
Marketwire  Sep 17  Comment 
NEW BRUNSWICK, NJ and LEIDEN, NETHERLANDS -- (Marketwire) -- 09/17/10 -- Johnson & Johnson (NYSE: JNJ) and Crucell N.V. (NYSE Euronext, NASDAQ: CRXL) (SWISS: CRX) today announced that they are in advanced negotiations for a potential public offer by
Marketwire  Aug 17  Comment 
LEIDEN, NETHERLANDS -- (Marketwire) -- 08/17/10 -- PRESS RELEASE Crucell Reports Record Revenues in Second Quarter 2010 Total revenues and other operating income of EUR128.6 million, a 63% growth compared to the same period in 2009 (EUR78.7 million).
Marketwire  Aug 11  Comment 
LEIDEN, NETHERLANDS -- (Marketwire) -- 08/11/10 -- Dutch biopharmaceutical company Crucell N.V. (NYSE Euronext, NASDAQ: CRXL) (SWISS: CRX) today announced that it will release its financial results for the second quarter 2010 on Tuesday August 17,
Marketwire  Aug 11  Comment 
LEIDEN, NETHERLANDS -- (Marketwire) -- 08/11/10 -- Dutch biopharmaceutical company Crucell N.V. (NYSE Euronext, NASDAQ: CRXL) (SWISS: CRX) today announces its intention to participate in an international Phase I clinical trial in the United States
Marketwire  Jul 8  Comment 
LEIDEN, NETHERLANDS -- (Marketwire) -- 07/08/10 -- Dutch biopharmaceutical company Crucell N.V. (NYSE Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced that Crucell and sanofi pasteur reached an agreement on a series of transactions to
Marketwire  Jun 24  Comment 
LEIDEN, NETHERLANDS -- (Marketwire) -- 06/24/10 -- Dutch biopharmaceutical company Crucell N.V. (NYSE Euronext, NASDAQ: CRXL) (SWISS: CRX) today announced the start of a discovery program leading to the development and commercialization of a
Marketwire  May 11  Comment 
LEIDEN, NETHERLANDS -- (Marketwire) -- 05/11/10 -- PRESS RELEASE Crucell Announces First Quarter 2010 Results Total revenues and other operating income of EUR65.7 million were lower compared to EUR73.7 million in Q109 due to phasing of shipments into





 


References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki